News

YSOPIA Bioscience Announces Leadership Team Reorganization and Appoints Co-Founder & CFO Fabrice Guez CEO & CFO

Nov 1, 2021

YSOPIA Bioscience, a French clinical stage biotechnology company specializing in the research and development of innovative biotherapies using the properties of keystone bacterial strains of the gut microbiome, today announced its leadership team reorganization. The Board has appointed Chief Finance Officer (CFO) Fabrice Guez CEO & CFO.

Fabrice Guez, an accomplished executive with more than two decades of experience within biotech environment and pharmaceutical SMEs, has been named CEO & CFO.

Fabrice co-founded YSOPIA Bioscience where he supervised 4 successful fundraising for a total of €20M. As CFO, he overseed corporate strategy, strategy implementation, financing, and financial management. Previously, as Supply chain Director at Oenobiol, he successfully headed up change management processes, thanks to his flexibility and excellent people skills.

Fabrice will be supported by the current members of the management team, that includes CSO Sandrine Claus, Senior Direction of Operations Frederic Elustondo, with the addition of Marion Soto, Director of Business Development.

Sandrine (PhD, MRSB)  joined YSOPIA Bioscience in 2017 as Chief Scientific Officer. She started studying the human gut microbiota at Imperial College London and served as Associate Professor in Integrative Metabolism at the University of Reading’s department of Food and Nutritional Sciences. She has over 50 scientific publications to her credit.

Frederic (PhD) will continue to lead as Senior Director of Operations. Frederic’s expertise focuses on project management and innovation in the different positions he held in the hospital & health care industry. He brought 4 innovative treatments in clinic at Cancer Research Technology (CRUK DL), RedX Pharma or Institut Bergonié.

Marion (PhD) is the Director of Business Development. Graduated from Ecole Polytechnique (France), she holds a PhD in Nutrition and Neurobiology from AgroParisTech and performed a postdoctoral fellowship at Harvard Medical School to study the impact of the gut microbiome on obesity and metabolic diseases. Marion has extensive expertise in in-licensing and non-dilutive fundings.

“The past year has been particularly important in the Company’s evolution, since YSOPIA reached a key milestone in advancing Christensenella to a successful Phase 1 clinical trial”, said Jean-Gérard Galvez, President YSOPIA Bioscience. “We have full confidence in YSOPIA’s senior management team to drive the business forward”.

 

Contacts
YSOPIA Bioscience, Corporate Communication
Caroline Bernard
caroline.bernard@ysopia.bio

 

In the same category

News

YSOPIA Bioscience Announces First Signs of Biological Activity from Phase I Analysis of Xla1, its...

Dec 2, 2021

more +
News

YSOPIA Successfully Completes Phase 1 Clinical Study of Xla1 Biotherapy for the Treatment of Obesity...

Jul 6, 2021

more +
News

90 seconds to learn more about YSOPIA Bioscience

Jun 1, 2021

more +

YSOPIA Bioscience © 2021 - all rights reserved terms and conditions